Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

September 30, 2006

Conditions
HIV Infections
Interventions
DRUG

Efavirenz + 2 NRTIs

DRUG

Lopinavir/Ritonavir + 2 NRTIs

PROCEDURE

Therapeutic Drug Monitoring

Trial Locations (13)

10457

Bronx-Lebanon Hosp. IMPAACT CRS, The Bronx

11794

SUNY Stony Brook NICHD CRS, Stony Brook

21287

Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore

38105

St. Jude/UTHSC CRS, Memphis

60614

Chicago Children's CRS, Chicago

70112

Tulane/LSU Maternal/Child CRS, New Orleans

70118

Children's Hosp., New Orleans

75235

Children's Med. Ctr. Dallas, Dallas

77030

Texas Children's Hosp. CRS, Houston

80045

Univ. of Colorado Denver NICHD CRS, Aurora

90027

Children's Hospital of Los Angeles NICHD CRS, Los Angeles

90806

Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach

91803

Usc La Nichd Crs, Alhambra

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00075907 - Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents | Biotech Hunter | Biotech Hunter